[Radiotherapy of cerebral metastases]

Radiotherapy of brain metastases is almost always palliative, as histologically documented cures are exceptional. Radiotherapy alone improves neurological symptoms in two-thirds of cases, but median survivals do not generally exceed 6 months. Whole brain radiation is mandatory as the lesions are often multiple, even when they escape clinical demonstration. There is no definite difference in prognosis after conventional rather than concentrated treatments. The role of steroids in the prevention and/or control of the acute effects of radiotherapy is controversial. Favorable prognostic factors are a good neurological and performance status, a solitary brain metastasis of a primary tumor under control, some histological types (i.e.: metastases from "oat" cell carcinomas, breast carcinomas, non-Hodgkin lymphomas are more responsive). Surgical excision before radiotherapy improves survival (6-12 months), especially in solitary metastases from melanomas, colon and renal tumors. Reirradiation can be useful, but the risk of delayed damage to the normal tissue in patients with longer survival (solitary operated and irradiated metastases) must be considered. The search for new radiotherapeutic modalities must be based on a deeper understanding of the biological factors involved in the response to radiation through controlled anatomo-clinical studies and biological research on experimental models.